We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
OCREVUS Roche Products Pty Ltd
Product name
OCREVUS
Sponsor
Accepted date
Jan-2026
Active ingredients
ocrelizumab
Summary of proposed indication
OCREVUS (ocrelizumab) is proposed for the treatment of:
-adults with relapsing forms of multiple sclerosis (MS). It is proposed that it slows down the worsening of physical disability and reduces how often relapses happen.
-adults with primary progressive multiple sclerosis (PPMS) by slowing the progression of physical disability.
-children aged 10 and older with relapsing–remitting multiple sclerosis (RRMS).
-adults with relapsing forms of multiple sclerosis (MS). It is proposed that it slows down the worsening of physical disability and reduces how often relapses happen.
-adults with primary progressive multiple sclerosis (PPMS) by slowing the progression of physical disability.
-children aged 10 and older with relapsing–remitting multiple sclerosis (RRMS).
Application type
C (new indication)
Publication date
Jan-2026